Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03778814
Other study ID # ZZTCRT-006
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 1, 2018
Est. completion date December 30, 2033

Study information

Verified date February 2023
Source Second Affiliated Hospital of Guangzhou Medical University
Contact Zhenfeng Zhang, MD,PhD
Phone 0086-020-34153532
Email zhangzhf@gzhmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tumor organoids and TILs (and/or peripheral T cells) cultures will be established from fresh tissure of lung cancer and other solid tumors. Coculture will be utilized to screen tumor-responsive T cells which are further selected for monoclonal expansion and TCR cloning for engineered reconstitution of TCR-T cells. After verification by multiple in vitro and in vivo studies, a large number of TCR-T cells will be introduced back into the patients via vein, artery or fine needle punctured to the tumor, or combinations. In this phase I study, the safety, tolerance and preliminary efficacy of the TCR-T cell immunotherapy on human will firstly be assessed.


Description:

1. Choose appropriate patients with KK-LC-1 expression in advanced lung cancer or other solid tumors and matched MHC-A11 typing, with written consent for this study; For cancer without expression of KK-LC-1, fresh tumor tissue should be obtained for RNA/DNA sequencing to computationally identify neoantigen peptides that can be captured by specifically personizedly synthesized poly-MHCI which can be further used to fish appropriate T cells from the patient. 2. Perform biopsy to obtain tissue from tumor/lymph node for organoids, TILs, DC and T cells culture, coculture to screening anti-tumor T cells, establish and select monoclonal T cells for TCR cloning; 3. Clone TCR sequence that targets KK-LC-1 or neoantigens; collect PBMCs from the blood of the patients, isolate and activate the T cells and generate the TCR-T cells; 4. Test the quality and killing activity of the TCR-T cells in vitro and then transplant back the patients via systemic (vein and/or artery) or local injections, and follow up closely to collect related clinical data as needed; 5. Evaluate the clinical results as needed.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date December 30, 2033
Est. primary completion date December 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. patients with advanced lung tumor or other solid tumor where biopsy is obtainable 2. Life expectancy >12 weeks 3. Child-Pugh-Turcotte score <7 4. Adequate heart,lung,liver,kidney function 5. Available autologous transduced T cells with greater than or equal to 20% expression of targeted TCR sequences determined by flow-cytometry and killing of tumor cells greater than or equal to 20% in cytotoxicity assay 6. Informed consent explained to, understood by and signed by patient/ guardian. Patient/guardian given copy of informed consent. - Exclusion Criteria: 1. Had accepted gene therapy before; 2. Tumor size more than 25cm; 3. Severe virus infection such as HBV, HCV, HIV, et al 4. Known HIV positivity 5. History of lung transplantation 6. Active infectious disease related to bacteria, virus,fungi,et al 7. Other severe diseases that the investigators consider not appropriate; 8. Pregnant or lactating women 9. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day) 10. Other conditions that the investigators consider not appropriate.

Study Design


Intervention

Biological:
TCR-T cells
Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.

Locations

Country Name City State
China The Second Affiliated Hospital of Guangzhou Medical University Guanzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Second Affiliated Hospital of Guangzhou Medical University Tcell Immune (Guangzhou) Science and Technology Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Median TCR-T cell persistence Median TCR-T cell persistence will be measured by quantitative rt-PCR. Five years
Primary Number of Patients with Dose Limiting Toxicity A dose limiting toxicity is defined as any toxicity that is considered to be primarily related to the TCR-T cells, which is irreversible, or life threatening or hematologic or non-hematologic Grade 3-5. three months
Secondary Percent of Patients with best response as either complete remission or partial remission Response rates will be estimated as the percent of patients whose best response is either complete remission or partial remission by combining the data from the patients. To compare with historical data, a 95% confidence interval will be calculated for the response rate. three months
See also
  Status Clinical Trial Phase
Terminated NCT04551885 - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors Phase 1
Completed NCT05054348 - First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors Phase 1
Active, not recruiting NCT04474470 - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT06088004 - Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05055609 - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors Phase 1
Completed NCT04020185 - Safety and Efficacy Study of IMSA101 in Refractory Malignancies Phase 1/Phase 2
Withdrawn NCT05071846 - MVX-ONCO-2 in Advanced Solid Tumors Phase 1
Recruiting NCT05607199 - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics Phase 1
Active, not recruiting NCT04552288 - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Phase 2
Active, not recruiting NCT06026254 - A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial Phase 1
Recruiting NCT06032845 - Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11) Phase 2
Recruiting NCT06144671 - GT201 Injection For The Treatment Of Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06398418 - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors Phase 1
Recruiting NCT05276284 - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy Phase 1/Phase 2
Recruiting NCT04121442 - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04221204 - A Monotherapy in Subjects With Advanced Solid Tumors Phase 1
Terminated NCT03992326 - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors Phase 1
Terminated NCT05435339 - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy Phase 1/Phase 2
Recruiting NCT04981119 - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting NCT06075849 - Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent Phase 1